Latham & Watkins Advises SPR Therapeutics in US$650 Acquisition by Medtronic

Medtronic plc (NYSE: MDT), a global healthcare technology leader, has announced its intent to acquire SPR Therapeutics, Inc. (SPR), a privately held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for chronic pain management. The transaction consists of an upfront cash payment of approximately US$650 million for all the outstanding equity in SPR. This transaction is subject to customary closing conditions and regulatory approvals.

Latham & Watkins LLP represents SPR in the transaction with a corporate deal team led by Boston partners Hans Brigham and Julie Scallen, with associates Jihoo Kim and Andrew Wang. Advice was also provided on tax matters by Bay Area partner Katharine Moir, with associate Jay Khurana; on benefits matters by Boston partner Josh Friedman, with associate Rebecca Fishbein; on intellectual property matters by New York counsel Eliot Choy, with associate Patrick Chew; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Chad Leiper; on FDA matters by Washington, D.C. counsel Chad Jennings; on healthcare regulatory matters by Bay Area partner Betty Pang and Los Angeles counsel Yanyan Zhou; on antitrust matters by Washington, D.C. partner Patrick English, with associate Linda Wang; and on insurance matters by Los Angeles partner Harrison White.